Leaflet ALS-SELEGILINA 5mg tablets


Indicated for: Parkinson's disease

Route of administration: oral

Substance: selegiline (antiparkinsonian agent)

ATC: N04BD01 (Nervous system | Dopaminergic agents | Monoamine oxidase B inhibitors)

Selegiline is a medication used in the treatment of Parkinson's disease and, occasionally, major depression. It acts as a selective monoamine oxidase type B (MAO-B) inhibitor, increasing dopamine levels in the brain and improving motor symptoms of Parkinson's disease.

The medication is taken orally, as directed by a doctor, usually once or twice daily. It is important for patients to follow the treatment regimen and avoid tyramine-rich foods to prevent adverse reactions.

Patients should be aware of potential side effects, such as dizziness, nausea, or insomnia. It is important to inform the doctor of any unusual symptoms.

Common side effects include dizziness, nausea, and insomnia. In rare cases, severe reactions such as high blood pressure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about ALS-SELEGILINA 5mg

  • Substance: selegiline
  • Date of last drug list: 01-07-2013
  • Commercial code: W41866001
  • Concentration: 5mg
  • Pharmaceutical form: tablets
  • Quantity: 60
  • Product type: generic
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Pharmaceutical forms available for selegiline

Concentrations available for selegiline

  • 10mg
  • 5mg